Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBUNASDAQ:IFRXNASDAQ:PMNNASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$0.85-0.2%$0.94$0.66▼$3.93$79.27M2.361.57 million shs786,345 shsIFRXInflaRx$1.70+17.2%$1.19$0.82▼$2.82$114.13M2.21229,125 shs519,721 shsPMNProMIS Neurosciences$0.62+6.3%$0.67$0.51▼$2.37$20.26M0.2872,712 shs12,723 shsSGMTSagimet Biosciences$3.45+0.9%$3.12$1.73▼$7.38$105.83M2.4860,830 shs430,041 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences+10.44%+1.99%-9.24%-36.40%-77.45%IFRXInflaRx+18.85%+25.00%+26.09%-35.27%+4.32%PMNProMIS Neurosciences-3.33%-4.24%-19.59%-34.79%-70.85%SGMTSagimet Biosciences+3.32%+34.12%-7.82%-15.56%-19.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences2.46 of 5 stars3.52.00.00.01.63.30.6IFRXInflaRx2.7841 of 5 stars3.53.00.00.03.41.70.6PMNProMIS Neurosciences2.8524 of 5 stars3.52.00.00.03.82.50.6SGMTSagimet Biosciences2.6282 of 5 stars3.42.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 3.00Buy$9.33996.88% UpsideIFRXInflaRx 3.00Buy$9.33449.02% UpsidePMNProMIS Neurosciences 3.00Buy$6.00867.90% UpsideSGMTSagimet Biosciences 2.80Moderate Buy$22.40549.28% UpsideCurrent Analyst Ratings BreakdownLatest PMN, SGMT, IFRX, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.004/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/26/2025IFRXInflaRxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/19/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/11/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/7/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/26/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.99M7.92N/AN/A$4.17 per share0.20IFRXInflaRx$165.79K688.38N/AN/A$1.89 per share0.90PMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ASGMTSagimet Biosciences$2M52.91N/AN/A$3.98 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$102.07M-$1.65N/AN/AN/A-1,290.81%-45.46%-38.07%5/6/2025 (Estimated)IFRXInflaRx-$46.18M-$0.87N/AN/AN/A-33,362.70%-65.98%-56.86%5/6/2025 (Estimated)PMNProMIS Neurosciences-$13.21M-$0.03N/AN/AN/AN/A-636.20%-130.32%5/13/2025 (Estimated)SGMTSagimet Biosciences-$27.88M-$1.43N/AN/AN/AN/A-23.63%-22.91%5/21/2025 (Estimated)Latest PMN, SGMT, IFRX, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025SGMTSagimet Biosciences-$0.79N/AN/AN/AN/AN/A5/14/2025Q1 2025IFRXInflaRx-$0.18N/AN/AN/A$0.03 millionN/A5/13/2025Q1 2025PMNProMIS Neurosciences-$0.14N/AN/AN/AN/AN/A5/6/2025Q1 2025CRBUCaribou Biosciences-$0.42N/AN/AN/AN/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/20/2025Q4 2024IFRXInflaRx-$0.27-$0.09+$0.18-$0.09$0.13 millionN/A3/12/2025Q4 2024SGMTSagimet Biosciences-$0.65-$0.50+$0.15-$0.50N/AN/A3/10/2025Q4 2024CRBUCaribou Biosciences-$0.40-$0.39+$0.01-$0.39$2.11 million$2.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A7.387.38IFRXInflaRxN/A5.314.61PMNProMIS NeurosciencesN/A9.309.30SGMTSagimet BiosciencesN/A38.4138.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%IFRXInflaRx42.39%PMNProMIS Neurosciences50.13%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences9.50%IFRXInflaRx16.30%PMNProMIS Neurosciences4.40%SGMTSagimet Biosciences17.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.01 million81.95 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionablePMNProMIS Neurosciences532.69 million31.25 millionNot OptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionablePMN, SGMT, IFRX, and CRBU HeadlinesRecent News About These CompaniesBlue Owl Capital Holdings LP Has $5.96 Million Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT)April 26, 2025 | marketbeat.comSagimet Biosciences announces presentations at EASL Congress 2025April 25, 2025 | markets.businessinsider.comSagimet Biosciences to Present Phase 2b FASCINATE-2 Study Findings on Denifanstat at EASL Congress 2025April 23, 2025 | quiverquant.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 7.11%April 23, 2025 | aaii.comSagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025April 23, 2025 | finance.yahoo.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 14.92%April 7, 2025 | aaii.comSagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Down 15.9% in MarchApril 2, 2025 | marketbeat.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 12.37%March 31, 2025 | aaii.comSagimet Biosciences Gets Clearance To Initiate Phase 1 Study Of TVB-3567 For Treatment Of AcneMarch 13, 2025 | nasdaq.comSagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 12, 2025 | finanznachrichten.deSagimet Biosciences reports Q4 EPS (50c), consensus (63c)March 12, 2025 | markets.businessinsider.comSagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate UpdatesMarch 12, 2025 | globenewswire.comSagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567March 11, 2025 | markets.businessinsider.comSagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 11, 2025 | globenewswire.comSagimet Biosciences' Denifanstat Should Be Worth More TodayMarch 7, 2025 | seekingalpha.comIs Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?February 25, 2025 | msn.comIs Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?February 25, 2025 | msn.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 10.56%February 25, 2025 | aaii.com10 Hot Penny Stocks to Buy NowFebruary 24, 2025 | insidermonkey.comSagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy NowFebruary 22, 2025 | insidermonkey.comSagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone SymposiumFebruary 19, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMN, SGMT, IFRX, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$0.85 0.00 (-0.16%) As of 04:00 PM EasternCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.InflaRx NASDAQ:IFRX$1.70 +0.25 (+17.24%) As of 04:00 PM EasternInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.ProMIS Neurosciences NASDAQ:PMN$0.62 +0.04 (+6.33%) As of 03:55 PM EasternProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Sagimet Biosciences NASDAQ:SGMT$3.45 +0.03 (+0.88%) As of 04:00 PM EasternSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
